Trial Profile
Antimuscarinic Medication for Urgency Urinary Incontinence in Women With Dual Incontinence (Darifenacin for Treatment of Women With Dual Incontinence)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Darifenacin (Primary)
- Indications Faecal incontinence; Urinary incontinence
- Focus Therapeutic Use
- Acronyms BAMA
- 01 Sep 2021 Primary endpoint (change in FI symptom severity) has been met, according to Results published in the International Urogynecology Journal.
- 01 Sep 2021 Results published in the International Urogynecology Journal.
- 18 Jan 2019 Status changed from recruiting to completed.